EC	TION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
1	Product identifier: INDIAN SANDALWOOD
	Other means of identification:
	Not relevant
2	Relevant identified uses of the substance or mixture and uses advised against:
	Relevant uses: Essence
	Uses advised against: All uses not specified in this section or in section 7.3
3	Details of the supplier of the safety data sheet:
	ECHOES MUM VE KOKU TASARIM PAZARLAMA VE SAN. A.Ş
	FERİKÖY FIRIN SOKAK NO: 69 KAT: 4 34360
	BOMONTİ / ŞİŞLİ - İSTANBUL
	T + 90 212 231 41 54
	info@candlelab.com.tr - www.candlelab.com.tr
4	Emergency telephone number: 114
EC	TION 2: HAZARDS IDENTIFICATION
1	Classification of the substance or mixture:
	CLP Regulation (EC) No 1272/2008:
	Classification of this product has been carried out in accordance with CLP Regulation (EC) No 1272/2008.
	Aquatic Chronic 2: Hazardous to the aquatic environment, long-term hazard, Category 2, H411
	Skin Irrit. 2: Skin irritation, Category 2, H315
2	Skin Sens. 1: Sensitisation, skin, Category 1, H317 Label elements:
-	CLP Regulation (EC) No 1272/2008:
	Hazard statements:
	Aquatic Chronic 2: H411 - Toxic to aquatic life with long lasting effects. Skin Irrit. 2: H315 - Causes skin irritation.
	Skin Sens. 1: H317 - May cause an allergic skin reaction.
	Precautionary statements:
	P264: Wash thoroughly after handling.
	P273: Avoid release to the environment. P302+P352: IF ON SKIN: Wash with plenty of water.
	P333+P313: If skin irritation or rash occurs: Get medical advice/attention. P391: Collect spillage.
	Supplementary information:
	$Contains \ [1s-(1\alpha,3a\beta,4\alpha,8a\beta)] - decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene, \ 1,2,3,5,6,7-hexahydro-1,1,2,3,3-methylene-1,4-methanoazulene, \ 1,2,3,5,6,7-hexahydro-1,1,2,3,3-methylene-1,4-methylene-1,1-methylene-1,4-methylene-1,4-methylene-1,4-methylene-1,4-$
	pentamethyl-4H-inden-4-one, Bulnesia sarmienti, ext., acetate, Caryophyllene. Substances that contribute to the classification
	1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
3	Other hazards:
5	Product does not meet PBT/vPvB criteria
	Endocrine-disrupting properties: The product does not meet the criteria.
EC	TION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Date of compilation: 25/11/2024 Version: 1

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS (continued)

3.1 Substance:

Non-applicable

3.2 Mixture:

Chemical description: Mixture based on aromatising substances and preparations.

Components:

In accordance with Annex II of Regulation (EC) No 1907/2006 (point 3), the product contains:

Identification	Chemical name/Classification	Concentration
CAS: 54464-57-2 EC: 259-174-3 Index: Non-applicable REACH:Non-applicable	1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Chronic 1: H410; Skin Irrit. 2: H315; Skin Sens. 1: H317 - Warning	10 - <25 %
CAS: 105-95-3 EC: 203-347-8 Index: Non-applicable REACH:01-2119976314-33- XXXX	1,4-dioxacycloheptadecane-5,17-dione ⁽²⁾ Not classified Regulation 1272/2008 Image: Classified state s	10 - <25 %
CAS: 33704-61-9 EC: 251-649-3 Index: Non-applicable REACH:01-2119977131-40- XXXX	1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Chronic 2: H411; Eye Irrit. 2: H319; Skin Irrit. 2: H315; Skin Sens. 1B: H317 - Warning	0,1 - <1 %
CAS: 94333-88-7 EC: 305-067-2 Index: Non-applicable REACH:01-2120746528-45- XXXX	Bulnesia sarmienti, ext., acetate ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Acute 1: H400; Aquatic Chronic 1: H410; Skin Irrit. 2: H315; Skin Sens. 1B: H317 - Warning	0,1 - <1 %
CAS: 3407-42-9 EC: 222-294-1 Index: Non-applicable REACH:01-2119979583-21- XXXX	3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Chronic 2: H411; Eye Irrit. 2: H319; Repr. 2: H361 - Warning	0,1 - <1 %
CAS: 469-61-4 EC: 207-418-4 Index: Non-applicable REACH:Non-applicable	Alpha-cedrene ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Acute 1: H400; Aquatic Chronic 1: H410; Asp. Tox. 1: H304 - Danger	0,1 - <1 %
CAS: 475-20-7 EC: 207-491-2 Index: Non-applicable REACH:01-2120936413-58- XXXX	[1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Acute 1: H400; Aquatic Chronic 1: H410; Asp. Tox. 1: H304; Skin Sens. 1B: H317 - Danger Image: Image	0,1 - <1 %
CAS: 128-37-0 EC: 204-881-4 Index: Non-applicable REACH:01-2119565113-46- XXXX	2,6-di-tert-butyl-p-cresol ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Acute 1: H400; Aquatic Chronic 1: H410 - Warning	0,1 - <1 %
CAS: 87-44-5 EC: 201-746-1 Index: Non-applicable REACH:01-2120745237-53- XXXX	Caryophyllene ⁽¹⁾ Self-classified Regulation 1272/2008 Asp. Tox. 1: H304; Skin Sens. 1B: H317 - Danger	0,1 - <1 %
CAS: 546-28-1 EC: 208-898-8 Index: Non-applicable REACH:Non-applicable	[3R-(3α,3aβ,7β,8aα)]-octahydro-3,8,8-trimethyl-6-methylene-1H-3a,7-methanoazulene ⁽¹⁾ Self-classified Regulation 1272/2008 Aquatic Acute 1: H400; Asp. Tox. 1: H304 - Danger Self-classified	<0,1 %

⁽¹⁾ Substances presenting a health or environmental hazard which meet criteria laid down in Regulation (EU) No. 2020/878 ⁽²⁾ Voluntarily-listed substance failing to meet any of the criteria set out in Regulation (EU) No. 2020/878

Version: 1

To obtain more information on the hazards of the substances consult sections 11, 12 and 16.

Other information:

	Identification		M-factor
Alpha-cedrene		Acute	10
CAS: 469-61-4	EC: 207-418-4	Chronic	10
[3R-(3α,3aβ,7β,8aα)]-oct	tahydro-3,8,8-trimethyl-6-methylene-1H-3a,7-methanoazulene	Acute	10
CAS: 546-28-1	EC: 208-898-8	Chronic	10

Date of compilation: 25/11/2024 Version: 1

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures:

The symptoms resulting from intoxication can appear after exposure, therefore, in case of doubt, seek medical attention for direct exposure to the chemical product or persistent discomfort, showing the SDS of this product. **By inhalation:**

This product does not contain substances classified as hazardous for inhalation.

By skin contact:

Remove contaminated clothing and footwear, rinse skin or shower the person affected if appropriate with plenty of cold water and neutral soap. In serious cases see a doctor. If the product causes burns or freezing, clothing should not be removed as this could worsen the injury caused if it is stuck to the skin. If blisters form on the skin, these should never be burst as this will increase the risk of infection.

By eye contact:

Rinse eyes thoroughly with lukewarm water for at least 15 minutes. Do not allow the person affected to rub or close their eyes. If the injured person uses contact lenses, these should be removed unless they are stuck to the eyes, in which case this could cause further damage. In all cases, after cleaning, a doctor should be consulted as quickly as possible with the SDS of the product.

By ingestion/aspiration:

Do not induce vomiting, but if it does happen keep the head down to avoid aspiration. Keep the person affected at rest. Rinse out the mouth and throat, as they may have been affected during ingestion.

4.2 Most important symptoms and effects, both acute and delayed:

Acute and delayed effects are indicated in sections 2 and 11.

4.3 Indication of any immediate medical attention and special treatment needed:

Not relevant

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media:

Suitable extinguishing media:

Product is non-flammable under normal conditions of storage, handling and use. In the case of combustion as a result of improper handling, storage or use preferably use polyvalent powder extinguishers (ABC powder), in accordance with the Regulation on fire protection systems.

Unsuitable extinguishing media:

Non-applicable

5.2 Special hazards arising from the substance or mixture:

As a result of combustion or thermal decomposition reactive sub-products are created that can become highly toxic and, consequently, can present a serious health risk.

5.3 Advice for firefighters:

Depending on the magnitude of the fire it may be necessary to use full protective clothing and self-contained breathing apparatus (SCBA). Minimum emergency facilities and equipment should be available (fire blankets, portable first aid kit,...) in accordance with Directive 89/654/EC.

Additional provisions:

Act in accordance with the Internal Emergency Plan and the Information Sheets on actions to take after an accident or other emergencies. Eliminate all sources of ignition. In case of fire, cool the storage containers and tanks for products susceptible to combustion, explosion or BLEVE as a result of high temperatures. Avoid spillage of the products used to extinguish the fire into an aqueous medium.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures:

Version: 1

For non-emergency personnel:



Date of compilation: 25/11/2024 Version: 1

SECTION 6: ACCIDENTAL RELEASE MEASURES (continued)	

Isolate leaks provided that there is no additional risk for the people performing this task. Personal protection equipment must be used against potential contact with the spilt product (See section 8). Evacuate the area and keep out those who do not have protection.

For emergency responders:

Wear protective equipment. Keep unprotected persons away. See section 8.

6.2 Environmental precautions:

Avoid at all cost any type of spillage into an aqueous medium. Contain the product absorbed appropriately in hermetically sealed containers. Notify the relevant authority in case of exposure to the general public or the environment.

6.3 Methods and material for containment and cleaning up:

It is recommended:

Absorb the spillage using sand or inert absorbent and move it to a safe place. Do not absorb in sawdust or other combustible absorbents. For any concern related to disposal consult section 13.

6.4 Reference to other sections:

See sections 8 and 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling:

A.- General precautions for safe use

Comply with the current legislation concerning the prevention of industrial risks with regards manually handling weights. Maintain order, cleanliness and dispose of using safe methods (section 6).

B.- Technical recommendations for the prevention of fires and explosions

Product is non-flammable under normal conditions of storage, handling and use. It is recommended to transfer at slow speeds to avoid the generation of electrostatic charges that can affect flammable products. Consult section 10 for information on conditions and materials that should be avoided.

C.- Technical recommendations on general occupational hygiene

Do not eat or drink during the process, washing hands afterwards with suitable cleaning products.

D.- Technical recommendations to prevent environmental risks

Due to the danger of this product for the environment it is recommended to use it within an area containing contamination control barriers in case of spillage, as well as having absorbent material in close proximity.

7.2 Conditions for safe storage, including any incompatibilities:

A.- Specific storage requirements

Minimum Temp.: Maximum Temp.:

B.- General conditions for storage

Avoid sources of heat, radiation, static electricity and contact with food. For additional information see subsection 10.5

7.3 Specific end use(s):

Except for the instructions already specified it is not necessary to provide any special recommendation regarding the uses of this product.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Version: 1

8.1 Control parameters:

Substances whose occupational exposure limits have to be monitored in the workplace (European OEL, not country-specific legislation):

There are no applicable occupational exposure limits for the substances contained in the product

DNEL (Workers):

Date of compilation: 25/11/2024 Version: 1

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION (continued)

		Short	exposure	Long	exposure
Identification		Systemic	Local	Systemic	Local
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4- one	Oral	Not relevant	Not relevant	Not relevant	Not relevant
CAS: 33704-61-9	Dermal	Not relevant	Not relevant	0,42 mg/kg	Not relevant
EC: 251-649-3	Inhalation	Not relevant	Not relevant	1,47 mg/m ³	Not relevant
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	Oral	Not relevant	Not relevant	Not relevant	Not relevant
CAS: 3407-42-9	Dermal	Not relevant	Not relevant	3,75 mg/kg	Not relevant
EC: 222-294-1	Inhalation	Not relevant	Not relevant	13,2 mg/m ³	Not relevant
2,6-di-tert-butyl-p-cresol	Oral	Not relevant	Not relevant	Not relevant	Not relevant
CAS: 128-37-0	Dermal	Not relevant	Not relevant	0,5 mg/kg	Not relevant
EC: 204-881-4	Inhalation	Not relevant	Not relevant	3,5 mg/m ³	Not relevant

DNEL (General population):

		Short e	exposure	Long e	exposure
Identification		Systemic	Local	Systemic	Local
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one	Oral	Not relevant	Not relevant	0,25 mg/kg	Not relevant
CAS: 33704-61-9	Dermal	Not relevant	Not relevant	0,25 mg/kg	Not relevant
EC: 251-649-3	Inhalation	Not relevant	Not relevant	0,44 mg/m ³	Not relevant
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	Oral	Not relevant	Not relevant	1,88 mg/kg	Not relevant
CAS: 3407-42-9	Dermal	Not relevant	Not relevant	1,88 mg/kg	Not relevant
EC: 222-294-1	Inhalation	Not relevant	Not relevant	3,26 mg/m ³	Not relevant
2,6-di-tert-butyl-p-cresol	Oral	Not relevant	Not relevant	Not relevant	Not relevant
CAS: 128-37-0	Dermal	Not relevant	Not relevant	0,25 mg/kg	Not relevant
EC: 204-881-4	Inhalation	Not relevant	Not relevant	0,86 mg/m ³	Not relevant

PNEC:

Identification				
1,4-dioxacycloheptadecane-5,17-dione	STP	124 mg/L	Fresh water	0,00187 mg/L
CAS: 105-95-3	Soil	0,25 mg/kg	Marine water	0,000187 mg/L
EC: 203-347-8	Intermittent	0,0187 mg/L	Sediment (Fresh water)	1,26 mg/kg
	Oral	0,0333 g/kg	Sediment (Marine water)	0,13 mg/kg
$1,2,3,5,6,7\mbox{-hexahydro-1},1,2,3,3\mbox{-pentamethyl-4H-inden-4-one}$	STP	10 mg/L	Fresh water	0,004 mg/L
CAS: 33704-61-9	Soil	0,0174 mg/kg	Marine water	0 mg/L
EC: 251-649-3	Intermittent	Not relevant	Sediment (Fresh water)	0,0991 mg/kg
	Oral	0,00111 g/kg	Sediment (Marine water)	0,00991 mg/kg
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	STP	0,1 mg/L	Fresh water	0,00296 mg/L
CAS: 3407-42-9	Soil	0,0128 mg/kg	Marine water	0,000296 mg/L
EC: 222-294-1	Intermittent	0,0259 mg/L	Sediment (Fresh water)	0,0725 mg/kg
	Oral	Not relevant	Sediment (Marine water)	0,00725 mg/kg
2,6-di-tert-butyl-p-cresol	STP	0,17 mg/L	Fresh water	0,000199 mg/L
CAS: 128-37-0	Soil	0,04769 mg/kg	Marine water	0,00002 mg/L
EC: 204-881-4	Intermittent	0,00199 mg/L	Sediment (Fresh water)	0,0996 mg/kg
	Oral	0,00833 g/kg	Sediment (Marine water)	0,00996 mg/kg

8.2 Exposure controls:

A.- Individual protection measures, such as personal protective equipment

As a preventative measure it is recommended to use basic Personal Protective Equipment, with the corresponding <<CE marking>> in accordance with Regulation (EU) 2016/425. For more information on Personal Protective Equipment (storage, use, cleaning, maintenance, class of protection,...) consult the information leaflet provided by the manufacturer. For more information see subsection 7.1. All information contained herein is a recommendation which needs some specification from the labour risk prevention services as it is not known whether the company has additional measures at its disposal.

B.- Respiratory protection

echoés

INDIAN SANDALWOOD

_							
	Pictogram		PPE	Labelling	CEN Standard		Remarks
	Mandatory respiratory tract protection		sk for gases and vapours		EN 405:2002+A1:2010	contan	place when there is a taste or smell of the ninant inside the face mask. If the contam nes with warnings it is recommended to us isolation equipment.
C S	pecific protection	n for the ha	ands				
	Pictogram		PPE	Labelling	CEN Standard		Remarks
	Mandatory hand protection		e gloves against inor risks	CATI		prole profes C	ace gloves in case of any sign of damage. onged periods of exposure to the product isional users/industrials, we recommend u E III gloves in line with standards EN ISO I20:2020 and EN ISO 374-1:2016+A1:201
						al can n	ot be calculated in advance with t
	eliability and has		ю ре спескеа р	prior to the applicat	lion.		
	Pictogram		PPE	Labelling	CEN Standard		Remarks
	Mandatory face		c glasses against n/projections.	CATI	EN 166:2002 EN ISO 4007:2018		daily and disinfect periodically according f facturer's instructions. Use if there is a ris splashing.
E - B	protection ody protection						
L D	Pictogram		PPE	Labelling	CEN Standard		Remarks
_	rictogram	Wo	rk clothing	Labelling	OLINOLAIIdaid	Repl	ace before any evidence of deterioration.
			in county	CATI		perio profes in	adds of prolonged exposure to the product sional/industrial users CE III is recommer accordance with the regulations in EN ISC 2013, EN ISO 6530:2005, EN ISO 13688:2 EN 464:1994.
		Anti-sl	ip work shoes		EN ISO 20347:2022	perio profes	ace before any evidence of deterioration. ods of prolonged exposure to the product sional/industrial users CE III is recommer accordance with the regulations in EN IS(20345:2022 y EN 13832-1:2007
F A	dditional emerge	ency meas	ures	II			
	Emergency mea	asure	St	tandards	Emergency mea	sure	Standards
	Emergency sho	ower		SI Z358-1 111, ISO 3864-4:2011	Eyewash statio	ns	DIN 12 899 ISO 3864-1:2011, ISO 3864-4:2011
Envi	ronmental expo	sure cont	rols:				1
In ac of bo	cordance with the	e commun id its conta	ity legislation fo		the environment it is re ee subsection 7.1.D	ecomme	ended to avoid environmental spill
With	regard to Directiv	ve 2010/75	5/EU, this produ	ct has the followin	g characteristics:		
V	.O.C. (Supply):		0 % v	veight			
V	.O.C. density at	20 °C:	0 kg/r	m³ (0 g/L)			
A	verage carbon n	umber:	Not re	elevant			

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

*Not relevant due to the nature of the product, not providing information property of its hazards.

Version: 1

EC	TION 9: PHYSICAL AND CHEMICAL PROPER	RTIES (continued)
1	Information on basic physical and chemical prope	rties:
	For complete information see the product datasheet.	
	Appearance:	
	Physical state at 20 °C:	Liquid
	Appearance:	Not available
	Colour:	Light yellow , Colourless
	Odour:	Characteristic
	Odour threshold:	Not relevant *
	Volatility:	
	Boiling point at atmospheric pressure:	>40 °C
	Vapour pressure at 20 °C:	Not relevant *
	Vapour pressure at 50 °C:	Not relevant *
	Evaporation rate at 20 °C:	Not relevant *
	Product description:	
	Density at 20 °C:	Not relevant *
	Relative density at 20 °C:	0,956 – 0,966
	Dynamic viscosity at 20 °C:	Not relevant *
	Kinematic viscosity at 20 °C:	Not relevant *
	Kinematic viscosity at 40 °C:	Not relevant *
	Concentration:	Not relevant *
	pH:	Not relevant *
	Vapour density at 20 °C:	Not relevant *
	Partition coefficient n-octanol/water 20 °C:	Not relevant *
	Solubility in water at 20 °C:	Not relevant *
	Solubility properties:	Not relevant *
	Decomposition temperature:	Not relevant *
	Melting point/freezing point:	Not relevant *
	Flammability:	
	Flash Point:	122 °C
	Flammability (solid, gas):	Not relevant *
	Autoignition temperature:	>300 °C
	Lower flammability limit:	Not relevant *
	Upper flammability limit:	Not relevant *
	Particle characteristics:	
	Median equivalent diameter:	Non-applicable
2	Other information:	
	Information with regard to physical hazard classes	s:
	Explosive properties:	Not relevant *
	Oxidising properties:	Not relevant *
	Corrosive to metals:	Not relevant *
	Heat of combustion:	Not relevant *
	Aerosols-total percentage (by mass) of flammable components:	Not relevant *
	Other safety characteristics:	

Date of compilation: 25/11/2024 Version: 1 SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES (continued) Surface tension at 20 °C: Not relevant * Refraction index: Not relevant * *Not relevant due to the nature of the product, not providing information property of its hazards.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity:

No hazardous reactions are expected because the product is stable under recommended storage conditions. See section 7 from Safety Data Sheet.

10.2 Chemical stability:

Chemically stable under the indicated conditions of storage, handling and use.

10.3 Possibility of hazardous reactions:

Under the specified conditions, hazardous reactions that lead to excessive temperatures or pressure are not expected.

10.4 Conditions to avoid:

Applicable for handling and storage at room temperature:

Not applicable Not applicable Not applicable Not applicable Not applicable	Shock and friction	Contact with air	Increase in temperature	Sunlight	Humidity
	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable

10.5 Incompatible materials:

Acids	Water	Oxidising materials	Combustible materials	Others
Avoid strong acids	Not applicable	Not applicable	Not applicable	Avoid alkalis or strong bases

10.6 Hazardous decomposition products:

See subsection 10.3, 10.4 and 10.5 to find out the specific decomposition products. Depending on the decomposition conditions, complex mixtures of chemical substances can be released: carbon dioxide (CO₂), carbon monoxide and other organic compounds.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008:

The experimental information related to the toxicological properties of the product itself is not available

Dangerous health implications:

In case of exposure that is repetitive, prolonged or at concentrations higher than the recommended occupational exposure limits, adverse effects on health may result, depending on the means of exposure:

A- Ingestion (acute effect):

- Acute toxicity: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for consumption. For more information see section 3

- Corrosivity/Irritability: The consumption of a considerable dose can cause irritation in the throat, abdominal pain, nausea and vomiting.

- B- Inhalation (acute effect):
 - Acute toxicity : Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for inhalation. For more information see section 3.
 - Corrosivity/Irritability: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3.
- C- Contact with the skin and the eyes (acute effect):
 - Contact with the skin: Produces skin inflammation.
 - Contact with the eyes: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazardous for this effect. For more information see section 3.
- D- CMR effects (carcinogenicity, mutagenicity and toxicity to reproduction):



Carcinogenicity: Based on available data, the classification criteria are not met, as it does not contain substances classification (Iteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classification criteria are not met, as it does not contain substances classified as hazardous for gran toxicity (STOT) - single exposure: Specific target organ toxicity (STOT) - repeated exposure: Specific target organ toxicity (STOT) - repeated exposure: Specific target organ toxicity (STOT) - repeated exposure: Specific target organ toxicity (STOT) - repeated exposure: Specific target organ toxicity (STOT) - repeated exposure: Specific target organ toxicity (STOT) - repeated exposure: Star, Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. Star, Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. Apartario hazardous Apartario hazardous Aparta		N 11: TOXICOLOGICAL INFORMATION (continued)			
classified as hazardous for this effect. For more information see section 3. E- Sensitizing effects: - Respiratory: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous with sensitising effects. For more information see section 3. - Skin: Prolonged contact with the skin can result in episodes of ailergic contact dermatitis. F- Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Skin: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazard the for this effect. For more information see section 3. - Karin: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard this effect. For more information see section 3. Other information: Not relevant Specific toxicology information on the substances: 		 hazardous for the effects mentioned. For more information see section IARC: 2,6-di-tert-butyl-p-cresol (3) Mutagenicity: Based on available data, the classification criteria ar hazardous for this effect. For more information see section 3. 	on 3. re not met, as it does	not contain substance	es classified a
Respiratory: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous with sensitising effects. For more information see section 3. Skin: Prolonged contact with the skin can result in episodes of allergic contact dematitis. Specific target organ toxicity (STOT) - single exposure: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous effect. For more information see section 3. Skin: Breaded on available data, the classification criteria are not met, as it does not contain substances classified as hazardous effect. For more information see section 3. Skin: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. Skin: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard this effect. For more information see section 3. Other information: Not relevant Specific toxicology information on the substances: Identification (Addeepfor2, 28.8-tetramethyl-2-naphthyl)ethan-1-one (L060 oral 2000 mg/kg C259-174-3 (L060 sinulation 22000 mg/kg C259-174-3 (L060 sinulation 22000 mg/kg C259-174-3 (L050 sinulation 22000 mg/kg C259-174-3 (L050 sinulation 2500 mg/kg C259-174-3 (L050 sinulation 2500 mg/kg C259-174-3 (L050 sinulation 2500 mg/kg C259-174-3 (L050 sinulation 2500 mg/kg C259-174-3 (L050 sinulation 2500 mg/kg C259 sinulation 2500 mg/kg C259 sinulation 2500 mg/kg C259-174-3 (L050 sinulation 250 mg/k C250 inflation 2500 mg/kg C259-174-3 (L050 sinulation 250 mg/k C250 mg/kg C259-174-3 (L050 sinulation 250 mg/k C250 mg/kg C259-174-3 (L050 sinulation 250 mg/k C250 mg/kg C2500 mg/kg C250 mg/kg C250 mg/kg C250 mg/kg C250 m				,	
hazardous with sensitising effects. For more information see section 3. - Skin: Prolonged contact with the skin can result in expisodes of allergic contact dermatitis. F- Specific target organ toxicity (STOT) - single exposure: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous effect. For more information see section 3. G- Specific target organ toxicity (STOT)-repeated exposure: - Skin: Brased on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. - Skin: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. H- Aspiration hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard tries effect. For more information see section 3. Not relevant Specific toxicology information on the substances: Information: Not relevant Specific toxicology information on the substances: Information: Information: Information: Information: Information: Information: Information: Information:	E-	Sensitizing effects:			
F- Specific target organ toxicity (STOT) - single exposure: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous of Specific target organ toxicity (STOT) repeated exposure: - G- Specific target organ toxicity (STOT) -repeated exposure: - Specific target organ toxicity (STOT) -repeated exposure: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazardous for this effect. For more information see section 3. Skin: Based on available data, the classification criteria are not met. as it does not contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Coto information		hazardous with sensitising effects. For more information see section	3.		classified as
effect. For more information see section 3. G- Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: S- Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: - Skin: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard: Based on available data, the classification criteria are not met. However, it does contain substanc			0		
G- Specific target organ toxicity (STOT)-repeated exposure: - Specific target organ toxicity (STOT)-repeated exposure: Based on available data, the classification criteria are not m does not contain substances classified as hazardous for this effect. For more information see section 3. H- Aspiration hazard: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazard this effect. For more information see section 3. H- Aspiration hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazar this effect. For more information see section 3. Other information Not relevant Specific toxicology information on the substances: Int (12,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one 1090 oral >2000 mg/kg 101 14.4 dioxacydoheptadecane-5,17-dione LD50 oral >2000 mg/kg 102 12,3,5,6,7,8-octahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral >2000 mg/kg 102 12,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral >2000 mg/kg 102 12,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral >2000 mg/kg 102 12,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral >2000 mg/kg 102			loes not contain subs	tances classified as ha	azardous for
does not contain substances classified as hazardous for this effect. For more information see section 3. - Skin: Based on available data, the classification criteria are not met, as it does not contain substances classified as hazard in the effect. For more information see section 3. H- Aspiration hazard: Based on available data, the classification criteria are not met. However, it does contain substances classified as hazard this effect. For more information see section 3. Other information: Not relevant Specific toxicology information on the substances: 2000 mg/kg (11,23,4,56,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthylyethan-1-one LD50 oral >2000 mg/kg CAS: 54464-57-2 LD50 dermal >2000 mg/kg 1 EC: 259-174-3 LD50 dermal >2000 mg/kg 1 1.4.disoacydoheptadeane-5,17-dione LD50 dermal >2000 mg/kg 1 1.2.3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2900 mg/kg 1 1.2.3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2900 mg/kg 1 CAS: 33704-61-9 LD50 oral 2900 mg/kg 1 1 CAS: 343-88-7 LD50 oral 2000 mg/kg 1 1 CAS: 3433-88-7 LD50 oral 2000 mg/kg 1 1 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Based on available data, the classification criteria are not met. However, it does contain substances classified as hazare this effect. For more information see section 3. Other information: Not relevant Specific toxicology information on the substances: Aduet toxicity Aduet toxicity 1/(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg CAS: 54464-57-2 LD50 oral >2000 mg/kg C Colspan="2">Set and the substances LD50 oral >2000 mg/kg C Colspan="2">Set and the substances LD50 oral >2000 mg/kg C Colspan="2">Set and the substances LD50 oral >2000 mg/kg C Colspan="2">Set and the substances LD50 oral >2000 mg/kg C Colspan="2">Set and the substances LD50 oral >2000 mg/kg C Colspan= t		does not contain substances classified as hazardous for this effect. F - Skin: Based on available data, the classification criteria are not me	For more information	see section 3.	
this effect. For more information see section 3. Other information: Not relevant Specific toxicology information on the substances: Internation: Addentification Addentification Internation: Internation: Colspan="2">Addentification Addentification Addentification Colspan="2">Addentification Colspan="2">Colspan="2">Colspan="2">Colspan="2" Colspan="2" Colspan= Add	H-	Aspiration hazard:			
Other information: Not relevant Specific toxicology information on the substances: Identification Acute toxicity 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg			ever, it does contain s	substances classified a	as hazardous
Not relevant Specific toxicology information on the substances: Identification Acute toxicity 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg IC CAS: 54464-57-2 LD50 dermal >2000 mg/kg IC IC EC: 259-174-3 LC60 inhalation >20 mg/L IC					
Specific toxicology information on the substances: Acute toxicity Acute toxicity 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg C CAS: 54464-57-2 LD50 oral >2000 mg/kg C EC: 259-174-3 LD50 oral >2000 mg/kg C 1,4-dioxacycloheptadecane-5,17-dione LD50 oral >2000 mg/kg C CAS: 105-95-3 LD50 oral >2000 mg/kg C EC: 203-347-8 LD50 oral 2000 mg/kg C 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2000 mg/kg C CAS: 33704-61-9 LD50 oral 2000 mg/kg C C EC: 203-847.8 LD50 oral 2000 mg/kg C C Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg C C S G S G G S G G S G G G G G G G G G G G G G G G	Oun	er mormation.			
Identification Acute toxicity 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg CAS: 54464-57-2 LD50 dermal >2000 mg/kg I EC: 259174-3 LC50 inhalation >20 mg/L I 1.4-dioxacycloheptadecane-5,17-dione LD50 dermal >2000 mg/kg I CAS: 105-95-3 LD50 dermal >2000 mg/kg I EC: 203-347-8 LC50 inhalation >5 mg/L I 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 dermal >2000 mg/kg I CAS: 33704-61-9 LD50 dermal >2000 mg/kg I I EC: 251-649-3 LD50 dermal >2000 mg/kg I I Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg I	Not	relevant			
Identification Acute toxicity 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg CAS: 54464-57-2 LD50 dermal >2000 mg/kg I EC: 259174-3 LC50 inhalation >20 mg/L I 1.4-dioxacycloheptadecane-5,17-dione LD50 dermal >2000 mg/kg I CAS: 105-95-3 LD50 dermal >2000 mg/kg I EC: 203-347-8 LC50 inhalation >5 mg/L I 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 dermal >2000 mg/kg I CAS: 33704-61-9 LD50 dermal >2000 mg/kg I I EC: 251-649-3 LD50 dermal >2000 mg/kg I I Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg I					
I-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one LD50 oral >2000 mg/kg I CAS: 54464-57-2 LD50 dermal >2000 mg/kg I EC: 259-174-3 LD50 oral >2000 mg/kg I 1,4-dioxacycloheptadecane-5,17-dione LD50 oral >2000 mg/kg I CAS: 105-95-3 LD50 dermal >2000 mg/kg I EC: 203-347-8 LC50 inhalation >5 mg/L I 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2900 mg/kg I CAS: 33704-61-9 LD50 dermal >2000 mg/kg I I EC: 251-649-3 LD50 dermal >2000 mg/kg I I Bulnesia sarmienti, ext., acetate LD50 dermal >2000 mg/kg I I CAS: 94333-88-7 LD50 dermal >2000 mg/kg I	Spe				
CAS: 54464-57-2 LD50 dermal >2000 mg/kg I EC: 259-174-3 LC50 inhalation >20 mg/L I 1.4-dioxacycloheptadecane-5,17-dione LD50 oral >2000 mg/kg I CAS: 105-95-3 LD50 dermal >2000 mg/kg I EC: 203-347-8 LD50 oral >2000 mg/kg I 1.2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2900 mg/kg I CAS: 33704-61-9 LD50 dermal >2000 mg/kg I I EC: 251-649-3 LD50 dermal >2000 mg/kg I I Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg I I EC: 305-067-2 LD50 oral 10000 mg/kg I I I I 3 (5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol LD50 oral >2000 mg/kg I I CAS: 3407-42-9 LD50 oral >2000 mg/kg I I I CAS: 3407-42-9 LD50 oral >2000 mg/kg I I I I I I I<	Spe	ecific toxicology information on the substances:			Geni
EC: 259-174-3 LC50 inhalation >20 mg/L Image: Constraint of the system of the sys	_	ecific toxicology information on the substances: Identification			Genu
CAS: 105-95-3 LD50 dermal >2000 mg/kg EC: 203-347-8 LC50 inhalation >5 mg/L 1 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 dermal 2900 mg/kg 1 CAS: 33704-61-9 LD50 dermal >2000 mg/kg 1 EC: 251-649-3 LD50 dermal >2000 mg/kg 1 Bulnesia samienti, ext., acetate LD50 dermal >2000 mg/kg 1 CAS: 94333-88-7 LD50 dermal >2000 mg/kg 1 EC: 305-067-2 LD50 dermal >2000 mg/kg 1 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol LD50 oral >2000 mg/kg 1 CAS: 3407-42-9 LD50 dermal >2000 mg/kg 1 1 S (5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol LD50 oral >2000 mg/kg 1 CAS: 3407-42-9 LD50 dermal >2000 mg/kg 1 1 EC: 222-294-1 LD50 oral >2000 mg/kg 1 1 Alpha-cedrene LD50 dermal >2000 mg/kg 1 1 CS2 inhalation >2000	1-(1	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one	LD50 oral	>2000 mg/kg	Genu
CAS: 105-95-3 LD50 dermal >2000 mg/kg EC: 203-347-8 LC50 inhalation >5 mg/L 1 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 dermal 2900 mg/kg 1 CAS: 33704-61-9 LD50 dermal >2000 mg/kg 1 EC: 251-649-3 LD50 dermal >2000 mg/kg 1 Bulnesia samienti, ext., acetate LD50 dermal >2000 mg/kg 1 CAS: 94333-88-7 LD50 dermal >2000 mg/kg 1 EC: 305-067-2 LD50 dermal >2000 mg/kg 1 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol LD50 oral >2000 mg/kg 1 CAS: 3407-42-9 LD50 dermal >2000 mg/kg 1 1 S (5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol LD50 oral >2000 mg/kg 1 CAS: 3407-42-9 LD50 dermal >2000 mg/kg 1 1 EC: 222-294-1 LD50 oral >2000 mg/kg 1 1 Alpha-cedrene LD50 dermal >2000 mg/kg 1 1 CS2 inhalation >2000	1-(1 CA	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2	LD50 oral LD50 dermal	>2000 mg/kg >2000 mg/kg	Genu
EC: 203-347-8 LC50 inhalation >5 mg/L I 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one LD50 oral 2900 mg/kg I CAS: 33704-61-9 LD50 dermal >2000 mg/kg I EC: 251-649-3 LC50 inhalation >5 mg/L I Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg I CAS: 94333-88-7 LD50 dermal >2000 mg/kg I EC: 305-067-2 LC50 inhalation >20 mg/L I 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol LD50 oral >2000 mg/kg I CAS: 3407-42-9 LD50 dermal >2000 mg/kg I I CAS: 3407-42-9 LD50 oral >2000 mg/kg I I CAS: 3407-42-9 LD50 oral >2000 mg/kg I I CAS: 3407-42-9 LD50 oral >2000 mg/kg I I CAS: 469-61-4 LD50 oral >2000 mg/kg I I CAS: 469-61-4 LD50 oral >2000 mg/kg I I CS0 inhalation <	1-(1 CA: EC:	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3	LD50 oral LD50 dermal LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L	Gent
CAS: 33704-61-9 LD50 dermal >2000 mg/kg EC: 251-649-3 LC50 inhalation >5 mg/L Image: Comparison of the symbol	1-(1 CA EC	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione	LD50 oral LD50 dermal LC50 inhalation LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg	Gent
CAS: 33704-61-9 LD50 dermal >2000 mg/kg EC: 251-649-3 LC50 inhalation >5 mg/L Image: Comparison of the symbol	1-(1 CA EC 1,4 CA	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg	Gent
EC: 251-649-3 LC50 inhalation >5 mg/L Image: constraint of the symbol of the symb	1-(1 CA EC 1,4 CA EC	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L	
Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg Bulnesia sarmienti, ext., acetate LD50 oral 10000 mg/kg I CAS: 94333-88-7 LD50 dermal >2000 mg/kg I EC: 305-067-2 LC50 inhalation >20 mg/L I 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol LD50 oral >5000 mg/kg I CAS: 3407-42-9 LD50 dermal >2000 mg/kg I EC: 222-294-1 LD50 dermal >200 mg/kg I Alpha-cedrene LD50 oral >2000 mg/kg I CAS: 469-61-4 LD50 dermal >2000 mg/kg I EC: 207-418-4 LD50 dermal >2000 mg/kg I [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg I CAS: 475-20-7 LD50 dermal >2000 mg/kg I I CAS: 475-20-7 LD50 dermal >2000 mg/kg I I EC: 207-491-2 LC50 inhalation >2000 mg/kg I I	1-(1 CA EC 1,4 CA EC	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg	
CAS: 94333-88-7 LD50 dermal >2000 mg/kg EC: 305-067-2 LC50 inhalation >20 mg/L 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol LD50 oral >5000 mg/kg CAS: 3407-42-9 LD50 dermal >2000 mg/kg EC: 222-294-1 LD50 oral >2000 mg/kg Alpha-cedrene LD50 oral >2000 mg/kg CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LD50 dermal >2000 mg/kg [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LD50 dermal >2000 mg/kg	1-(1 CA: EC: 1,4 EC: 1,2 CA:	Identification Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 oral LD50 dermal	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg	
EC: 305-067-2 LC50 inhalation >20 mg/L 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol LD50 oral >5000 mg/kg I CAS: 3407-42-9 LD50 dermal >2000 mg/kg I EC: 222-294-1 LD50 oral >200 mg/kg I Alpha-cedrene LD50 oral >2000 mg/kg I CAS: 469-61-4 LD50 dermal >2000 mg/kg I EC: 207-418-4 LD50 dermal >2000 mg/kg I [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg I CAS: 475-20-7 LD50 dermal >2000 mg/kg I I EC: 207-491-2 LD50 dermal >2000 mg/kg I I	1-(1 CA3 EC3 1,4 CA3 EC3 1,2 CA3 EC3	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol LD50 oral >5000 mg/kg CAS: 3407-42-9 LD50 dermal >2000 mg/kg EC: 222-294-1 LD50 oral >2000 mg/kg Alpha-cedrene LD50 oral >2000 mg/kg CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LD50 dermal >2000 mg/kg [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LD50 dermal >2000 mg/kg	1-(1 CA: EC: 1,4 CA: EC: 1,2, CA: EC: Bul	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate	LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >5 mg/L 10000 mg/kg	Ra
CAS: 3407-42-9 LD50 dermal >2000 mg/kg EC: 222-294-1 LC50 inhalation >20 mg/L Alpha-cedrene LD50 dermal >2000 mg/kg CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LC50 inhalation >20 mg/L [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg Image: Case of the second sec	1-(1 CA EC 1,4 CA EC CA EC Bull CA	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >5 mg/L 10000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
EC: 222-294-1 LC50 inhalation >20 mg/L Alpha-cedrene LD50 oral >2000 mg/kg CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LC50 inhalation >200 mg/kg [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LD50 dermal >2000 mg/kg	1-(1 CA EC 1,4 CA EC CA EC Bul CA EC	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 oral LD50 dermal	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
Alpha-cedrene LD50 oral >2000 mg/kg CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LC50 inhalation >20 mg/L [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LD50 dermal >2000 mg/kg	1-(1 CA: EC: 1,4 EC: CA: EC: Bul CA: EC: 3-(5	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LD50 dermal LD50 dermal LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
CAS: 469-61-4 LD50 dermal >2000 mg/kg EC: 207-418-4 LC50 inhalation >20 mg/L [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LD50 dermal >2000 mg/kg	1-(1 CA: EC: 1,4- CA: EC: Bul CA: EC: 3-(§ CA:	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,6,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol S: 3407-42-9	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >5 mg/L 2000 mg/kg >2000 mg/kg >2000 mg/kg >5 mg/L 10000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
EC: 207-418-4 LC50 inhalation >20 mg/L [1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LC50 inhalation >20 mg/L	1-(1 CA: EC: 1,4: CA: EC: Bul CA: EC: 3-(t CA: EC:	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one 8: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol S: 3407-42-9 : 222-294-1	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2000 mg/kg >2000 mg/kg	Ra
[1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene LD50 oral >2000 mg/kg CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LC50 inhalation >20 mg/L	1-(1 CA: EC: 1,4- CA: EC: 1,2, CA: EC: 3-(5 CA: EC: Alp	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one 8: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 oral LD50 oral LD50 dermal LC50 inhalation	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
CAS: 475-20-7 LD50 dermal >2000 mg/kg EC: 207-491-2 LC50 inhalation >20 mg/L	1-(1 CA: EC: 1,4. CA: EC: Bull CA: EC: 3-(t CA: EC: Alp CA:	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LC50 inhalation LD50 oral LD50 dermal LC50 inhalation LD50 dermal LC50 inhalation LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 dermal	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >55 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
EC: 207-491-2 LC50 inhalation >20 mg/L	1-(1 CA: EC: 1,4: CA: EC: Bul CA: EC: 3-(t CA: EC: Alp CA: EC:	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4 : 207-418-4	LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 oral LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
	1-(1 CA: EC: 1,4: CA: EC: Bull CA: EC: 3-(5 CA: EC: Alp CA: EC: [1s-	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4 : 207-418-4 -(10,3a,4,a,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene	LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >5 mg/L 2000 mg/kg >2000 mg/kg	Ra
	1-(1 CA: EC: 1,4. CA: EC: 1,2. CA: EC: 3-(\$ CA: EC: Alp CA: EC: [1s- CA: CA:	Actific toxicology information on the substances: Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4 : 207-418-4 -(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene S: 475-20-7	LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 dermal LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 dermal LD50 dermal	>2000 mg/kg >2000 mg/kg >20 mg/L >2000 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg >2000 mg/kg	Ra
	1-(1 CA: EC: 1,4: CA: EC: 1,2; CA: EC: 3-(5; CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: CA: EC: CA: CA: CA: CA: CA: CA: CA: CA: CA: C	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one S: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 .3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4 : 207-418-4 -(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene S: 475-20-7 : 207-491-2	LD50 oral LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 dermal LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 dermal LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral	>2000 mg/kg >200 mg/kg >20 mg/L >200 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg	Rat
CAS: 128-37-0 LD50 dermal >2000 mg/kg EC: 204-881-4 LC50 inhalation >5 mg/L	1-(1 CA: EC: 1,4: CA: EC: 1,2; CA: EC: 3-(£ CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: EC: CA: CA: CA: CA: CA: CA: CA: CA: CA: C	Identification 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one 5: 54464-57-2 : 259-174-3 -dioxacycloheptadecane-5,17-dione S: 105-95-3 : 203-347-8 -3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one S: 33704-61-9 : 251-649-3 nesia sarmienti, ext., acetate S: 94333-88-7 : 305-067-2 5,5,6-trimethylbicyclo[2.2.1]hept-2-yl]cyclohexan-1-ol S: 3407-42-9 : 222-294-1 ha-cedrene S: 469-61-4 : 207-418-4 (10,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene S: 475-20-7 : 207-491-2 -di-tert-butyl-p-cresol	LD50 oral LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 dermal LD50 oral LD50 oral LD50 dermal LD50 oral LD50 oral LD50 oral LD50 oral LD50 oral LD50 dermal LC50 inhalation LD50 dermal LD50 dermal LD50 dermal LD50 dermal LD50 dermal LD50 oral LD50 oral	>2000 mg/kg >200 mg/kg >200 mg/kg >200 mg/kg >2000 mg/kg >5 mg/L 2900 mg/kg >2000 mg/kg >5 mg/L 10000 mg/kg >2000 mg/kg	Genu Genu Rai Rai Rai Rai

Date of compilation: 25/11/2024 Version: 1

	A		Genus
Caryophyllene	LD50 oral	>5000 mg/kg	Rat
CAS: 87-44-5	LD50 dermal	>2000 mg/kg	
EC: 201-746-1	LC50 inhalation	>20 mg/L	
[3R-(3α,3aβ,7β,8aα)]-octahydro-3,8,8-trimethyl-6-methylene-1H-3a,7-methanoazulene	LD50 oral	>2000 mg/kg	
CAS: 546-28-1	LD50 dermal	>2000 mg/kg	

Acute Toxicity Estimate (ATE mix):

ATE mix		Ingredient(s) of unknown toxicity	
Oral	>2000 mg/kg (Calculation method)	Non-applicable	
Dermal	>2000 mg/kg (Calculation method)	Non-applicable	
Inhalation	>20 mg/L (4 h) (Calculation method)	Non-applicable	

11.2 Information on other hazards:

Endocrine disrupting properties

Endocrine-disrupting properties: The product does not meet the criteria.

Other information

Not relevant

SECTION 12: ECOLOGICAL INFORMATION

The experimental information related to the eco-toxicological properties of the product itself is not available

Toxic to aquatic life with long lasting effects.

12.1 Toxicity:

Acute toxicity:

Identification	Concentration		Species	Genus	
1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan- 1-one	LC50	>0.1 - 1 mg/L (96 h)		Fish	
CAS: 54464-57-2	EC50	>0.1 - 1 mg/L (48 h)		Crustacean	
EC: 259-174-3	EC50	>0.1 - 1 mg/L (72 h)		Algae	
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one	LC50	2,12 mg/L (96 h)	Oryzias latipes	Fish	
CAS: 33704-61-9	EC50	1,5 mg/L (48 h)	Daphnia magna	Crustacean	
EC: 251-649-3	EC50	10 mg/L (72 h)	Desmodesmus subspicatus	Algae	
Bulnesia sarmienti, ext., acetate	LC50	Not relevant			
CAS: 94333-88-7	EC50	0,33 mg/L (48 h)	Daphnia magna	Crustacean	
EC: 305-067-2	EC50	Not relevant			
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	LC50	17,6 mg/L (96 h)	Danio rerio	Fish	
CAS: 3407-42-9	EC50	2,59 mg/L (48 h)	Daphnia magna	Crustacean	
EC: 222-294-1	EC50	47 mg/L (72 h)	Desmodesmus subspicatus	Algae	
Alpha-cedrene	LC50	>0.1 - 1 mg/L (96 h)		Fish	
CAS: 469-61-4	EC50	>0.1 - 1 mg/L (48 h)		Crustacean	
EC: 207-418-4	EC50	>0.1 - 1 mg/L (72 h)		Algae	
[1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1,4- methanoazulene	LC50	Not relevant			
CAS: 475-20-7	EC50	0,119 mg/L (48 h)	Daphnia magna	Crustacean	
EC: 207-491-2	EC50	0,28 mg/L (72 h)	N/A	Algae	
2,6-di-tert-butyl-p-cresol	LC50	0,57 mg/L (96 h)	Brachydanio rerio	Fish	
CAS: 128-37-0	EC50	0,61 mg/L (48 h)	Daphnia magna	Crustacean	
EC: 204-881-4	EC50	Not relevant			

C	TION 12: ECOLOGICAL INFORMATION (cc	ntinued)				
	Identification		Concentration		Species	Genus
	[3R-(3α,3aβ,7β,8aα)]-octahydro-3,8,8-trimethyl-6-methylene-1 3a,7-methanoazulene	H- LC50	Not relevant			
	CAS: 546-28-1	EC50	0,015 mg/L (48 h)		QSAR	Fish
	EC: 208-898-8	EC50	Not relevant			
	Chronic toxicity:					
	Identification		Concentration		Species	Genus
	1,4-dioxacycloheptadecane-5,17-dione	NOEC	Not relevant			
	CAS: 105-95-3 EC: 203-347-8	NOEC	0,088 mg/L		Daphnia magna	Crustacea
	3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	NOEC	0,14 mg/L		N/A	Fish
	CAS: 3407-42-9 EC: 222-294-1	NOEC	Not relevant			
	2,6-di-tert-butyl-p-cresol	NOEC	0,053 mg/L		Oryzias latipes	Fish
	CAS: 128-37-0 EC: 204-881-4	NOEC	0,069 mg/L		Daphnia magna	Crustacea
2	Persistence and degradability:					
	Substance-specific information:					
	Identification		Degradability		Biodegradabi	lity
	1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-	BOD5	Not relevant	Concentration		100 mg/L
	one CAS: 33704-61-9	COD	Not relevant	Period		28 days
	EC: 251-649-3	BOD5/COD	Not relevant	% Biodegradab	le	0 %
	3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	BOD5	Not relevant	Concentration		4 mg/L
	CAS: 3407-42-9	COD	Not relevant	Period		28 days
	EC: 222-294-1	BOD5/COD	Not relevant	% Biodegradab	le	13,81 %
	[1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-	BOD5	Not relevant	Concentration		2 mg/L
	1,4-methanoazulene CAS: 475-20-7	COD	Not relevant	Period		28 days
	EC: 207-491-2	BOD5/COD	Not relevant	% Biodegradab	le	68 %
	2,6-di-tert-butyl-p-cresol	BOD5	Not relevant	Concentration		50 mg/L
	CAS: 128-37-0	COD	Not relevant	Period		28 days
	EC: 204-881-4	BOD5/COD	Not relevant	% Biodegradab	le	4,5 %
3	Bioaccumulative potential: Substance-specific information:				Bioaccumulation	potential
	1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one			BCF	82	
	CAS: 33704-61-9			Pow Log	4.2	
	EC: 251-649-3 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol			Potential BCF	Modera 1985	210
	CAS: 3407-42-9			Pow Log	1985	
	EC: 222-294-1			Potential	Very H	igh
	[1s-(1α,3aβ,4α,8aβ)]-decahydro-4,8,8-trimethyl-9-methylene-1	,4-methanoazi	llene	BCF		0
	CAS: 475-20-7			Pow Log	5	
	EC: 207-491-2			Potential		
	2,6-di-tert-butyl-p-cresol			BCF	1365	
	CAS: 128-37-0			Pow Log	5.1	
	EC: 204-881-4			Potential	Very H	igh
	[3R-(3a,3ab,7b,8aa)]-octahydro-3,8,8-trimethyl-6-methylene-1	H-3a,7-methar	noazulene	BCF	6000	
	CAS: 546-28-1			Pow Log	5.82	
	EC: 208-898-8			Potential	Very H	i er le

Date of compilation: 25/11/2024 Version: 1

Identification	Absorpt	ion/desorption	Va	
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4- one	Кос	200	Henry	Not relevant
CAS: 33704-61-9	Conclusion	Moderate	Dry soil	Not relevant
EC: 251-649-3	Surface tension	Not relevant	Moist soil	Not relevant
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol	Koc	209	Henry	Not relevant
CAS: 3407-42-9	Conclusion	Not relevant	Dry soil	Not relevant
EC: 222-294-1	Surface tension	Not relevant	Moist soil	Not relevant
2,6-di-tert-butyl-p-cresol	Koc	8183	Henry	3,42E-1 Pa⋅m³/n
CAS: 128-37-0	Conclusion	Not relevant	Dry soil	Yes
EC: 204-881-4	Surface tension	1,255E-2 N/m (258,85 °C)	Moist soil	Yes
$[3R{-}(3\alpha,3a\beta,7\beta,8a\alpha)]{-}octahydro{-}3,8,8{-}trimethyl{-}6{-}methylene{-}1H{-}3a,7{-}methanoazulene$	Koc	21700	Henry	39111,5 Pa·m³/r
CAS: 546-28-1	Conclusion	Immobile	Dry soil	Yes
EC: 208-898-8	Surface tension	Not relevant	Moist soil	Yes

12.5 Results of PBT and vPvB assessment:

Product does not meet PBT/vPvB criteria

12.6 Endocrine disrupting properties:

Endocrine-disrupting properties: The product does not meet the criteria.

12.7 Other adverse effects:

Not described

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods:

Code	Description	Waste class (Regulation (EU) No 1357/2014)
	It is not possible to assign a specific code, as it depends on the intended use by the user	Hazardous

Type of waste (Regulation (EU) No 1357/2014):

HP14 Ecotoxic, HP13 Sensitising

Waste management (disposal and evaluation):

Consult the authorized waste service manager on the assessment and disposal operations in accordance with Annex 1 and Annex 2 (Directive 2008/98/EC). As under 15 01 (2014/955/EC) of the code and in case the container has been in direct contact with the product, it will be processed the same way as the actual product. Otherwise, it will be processed as non-hazardous residue. Waste should not be disposed of to drains. See paragraph 6.2.

Regulations related to waste management:

In accordance with Annex II of Regulation (EC) No 1907/2006 (REACH) the community or state provisions related to waste management are stated

Community legislation: Directive 2008/98/EC, 2014/955/EU, Regulation (EU) No 1357/2014

SECTION 14: TRANSPORT INFORMATION

Transport of dangerous goods by land:

Version: 1

With regard to ADR 2023 and RID 2023:

Data of some listing OF/44/0004

INDIAN SANDALWOOD

Date of compilation: 25/11/2024	Version: 1	
SECTION 14: TRANSPO	ORT INFORMATION (continued)	
A A	UN number or ID number:UN proper shipping name:	UN3082 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1- one)
	.3 Transport hazard class(es):	9
	Labels:	9
	.4 Packing group:	
	1.5 Environmental hazards:	Yes
14	I.6 Special precautions for user Special regulations:	274, 335, 375, 601
	Tunnel restriction code:	-
	Physico-Chemical properties: Limited quantities:	see section 9 5 L
14	 Maritime transport in bulk according to IMO instruments: 	Not relevant
Transport of dange	-	
With regard to IMDG	• •	
14	.1 UN number or ID number:	UN3082
	UN proper shipping name:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one)
	I.3 Transport hazard class(es): Labels:	9 9
1/	.4 Packing group:	9
	1.5 Marine pollutant:	Yes
	 6 Special precautions for user Special regulations: 	335, 969, 274
	EmS Codes:	F-A, S-F
	Physico-Chemical properties:	see section 9
	Limited quantities:	5 L
	Segregation group:	Not relevant
14	.7 Maritime transport in bulk according to IMO instruments:	Not relevant
Transport of dange	rous goods by air:	
With regard to IATA/I	CAO 2024:	
	UN number or ID number:UN proper shipping name:	UN3082 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1- one)
14	I.3 Transport hazard class(es): Labels:	9 9
14	4.4 Packing group:	
	4.5 Environmental hazards:	Yes
14	.6 Special precautions for user	
	Physico-Chemical properties:	see section 9
14	I.7 Maritime transport in bulk according to IMO instruments:	Not relevant

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

- Article 95, REGULATION (EU) No 528/2012: Not relevant

Version: 1

Candidate substances for authorisation under the Regulation (EC) No 1907/2006 (REACH): Not relevant
 REGULATION (EU) No 649/2012, in relation to the import and export of hazardous chemical products: Not relevant

- Regulation (EU) No 2024/590, about substances that deplete the ozone layer. Not relevant
- Substances included in Annex XIV of REACH ("Authorisation List") and sunset date: Not relevant



Date of compilation: 25/11/2024 Version: 1

ECTION 15: R	EGULATORY INFORMATION (continued)		
Seveso III:			
Section	Description	Lower-tier requirements	Upper-tier requirements
E2	ENVIRONMENTAL HAZARDS	200	500

Shall not be used in:

---ornamental articles intended to produce light or colour effects by means of different phases, for example in ornamental lamps and ashtrays,

-tricks and jokes,

-games for one or more participants, or any article intended to be used as such, even with ornamental aspects.

Specific provisions in terms of protecting people or the environment:

It is recommended to use the information included in this safety data sheet as a basis for conducting workplace-specific risk assessments in order to establish the necessary risk prevention measures for the handling, use, storage and disposal of this product.

Other legislation:

The product could be affected by sectorial legislation

15.2 Chemical safety assessment:

The supplier has not carried out evaluation of chemical safety.

SECTION 16: OTHER INFORMATION

Legislation related to safety data sheets:

The SDS shall be supplied in an official language of the country where the product is placed on the market. This safety data sheet has been designed in accordance with ANNEX II-Guide to the compilation of safety data sheets of Regulation (EC) No 1907/2006 (COMMISSION REGULATION (EU) 2020/878).

Modifications related to the previous Safety Data Sheet which concerns the ways of managing risks.:

Not relevant

Texts of the legislative phrases mentioned in section 2:

H315: Causes skin irritation.

H317: May cause an allergic skin reaction.

H411: Toxic to aquatic life with long lasting effects.

Texts of the legislative phrases mentioned in section 3:

The phrases indicated do not refer to the product itself; they are present merely for informative purposes and refer to the individual components which appear in section 3

CLP Regulation (EC) No 1272/2008:

Aquatic Acute 1: H400 - Very toxic to aquatic life. Aquatic Chronic 1: H410 - Very toxic to aquatic life with long lasting effects. Aquatic Chronic 2: H411 - Toxic to aquatic life with long lasting effects. Asp. Tox. 1: H304 - May be fatal if swallowed and enters airways. Eye Irrit. 2: H319 - Causes serious eye irritation. Repr. 2: H361 - Suspected of damaging fertility or the unborn child. Skin Irrit. 2: H315 - Causes skin irritation. Skin Sens. 1: H317 - May cause an allergic skin reaction. Skin Sens. 1B: H317 - May cause an allergic skin reaction.

Version: 1

Classification procedure:

Skin Irrit. 2: Calculation method Skin Sens. 1: Calculation method Aquatic Chronic 2: Calculation method

Advice related to training:

Training is recommended in order to prevent industrial risks for staff using this product and to facilitate their comprehension and interpretation of this safety data sheet, as well as the label on the product.

Principal bibliographical sources:

http://echa.europa.eu http://eur-lex.europa.eu Abbreviations and acronyms:



Date of compilation: 25/11/2024 Version: 1
SECTION 16: OTHER INFORMATION (continued)
ADR: European agreement concerning the international carriage of dangerous goods by road IMDG: International maritime dangerous goods code IATA: International Air Transport Association ICAO: International Civil Aviation Organisation COD: Chemical Oxygen Demand BOD5: 5day biochemical oxygen demand BCF: Bioconcentration factor LD50: Lethal Dose 50 LC50: Lethal Dose 50 EC50: Effective concentration 50 EC50: Effective concentration 50 LogPOW: Octanolwater partition coefficient Koc: Partition coefficient of organic carbon UFI: unique formula identifier IARC: International Agency for Research on Cancer

DISCLAIMER OF LIABILITY The information in this SDS was obtained from sources which we believe are reliable. However, the information is provided without any warranty, express or implied, regarding its correctness. The conditions or methods of handling, storage, use or disposal of the product are beyond our control and may be beyond our knowledge. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product. This SDS was prepared and is to be used only for this product. If the product is used as a component in another product, this SDS information may not be applicable